Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncology Report

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/OR.16.2.249PMID 16820899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.

  2005cited by this paper
• Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

  2005cited by this paper
• Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors

  2004cited by this paper
• Molecular Prediction of Response to 5-Fluorouracil and Interferon-α Combination Chemotherapy in Advanced Hepatocellular Carcinoma

  2004cited by this paper
• Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-α/5-Fluorouracil against Hepatocellular Carcinoma

  2004cited by this paper
• Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

  2003cited by this paper
• Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

  2003cited by this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003cited by this paper
• Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma.

  2003cited by this paper
• A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

  2003influential reference
• Combined intraarterial 5‐fluorouracil and subcutaneous interferon‐α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

  2002cited by this paper
• Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.

  2002cited by this paper
• Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

  2001cited by this paper
• Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

  2001cited by this paper
• The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties.

  2001cited by this paper
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

  2001cited by this paper
• Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.

  2000cited by this paper
• Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon‐α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis

  2000cited by this paper
• Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.

  2000cited by this paper
• Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α‐interferon and oral tegafur/uracil

  2000cited by this paper
• Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.

  1999influential reference
• 5‐Fluorouracil and levofolinic acid with or without recombinant interferon‐2b in patients with advanced colorectal carcinoma

  1999influential reference
• A phase II study of 5‐fluorouracil, leucovorin, and interferon‐α in the treatment of patients with metastatic or recurrent gastric carcinoma

  1999cited by this paper
• Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.

  1999cited by this paper
• Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

  1999cited by this paper
• Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

  1999influential reference
• Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins

  1999cited by this paper
• 5-Fluorouracil plus interferon α-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: A multicentric randomized study

  1998influential reference
• STAT structure and function in signaling.

  1998cited by this paper
• Localization and expression of p27KIP1 in multistage colorectal carcinogenesis.

  1998cited by this paper
• The type I interferon receptor complex

  1997cited by this paper
• Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma

  1997cited by this paper
• Combination therapy with 5-fluorouracil and IFN-alpha2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells.

  1997cited by this paper
• Automated Double Labeling of Proliferation and Apoptosis in Glutathione S-transferase-positive Hepatocytes in Rats

  1997cited by this paper
• Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.

  1996cited by this paper
• Phase II clinical trial with 5‐fluorouracil, recombinant interferon‐α‐2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus

  1996cited by this paper
• A phase II trial of interferon alpha‐2A, 5‐fluorouracil, and cisplatin in patients with advanced esophageal carcinoma

  1995cited by this paper
• Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.

  1995influential reference
• Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

  1995influential reference
• Cytokine signaling through nonreceptor protein tyrosine kinases.

  1995cited by this paper
• Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

  1993cited by this paper
• Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

  1993cited by this paper
• Low serum alpha‐fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5‐fu and interferon‐alpha‐2b

  1993cited by this paper
• Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies.

  1993cited by this paper
• Treatment of carcinoma of the esophagus with 5‐fluorouracil and recombinant alfa‐2a‐interferon

  1993cited by this paper
• Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial

  1993influential reference
• Cytokine triggered molecular pathways that control cell cycle arrest

  1992cited by this paper
• Inhibition of angiogenesis.

  1992cited by this paper
• Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.

  1992influential reference
• Combination of 5‐Fluorouracil and Recombinant Interferon α‐2B in Advanced Gastric Cancer: A Phase I Study

  1992influential reference
• Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.

  1991cited by this paper
• Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.

  1990cited by this paper
• Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

  1989cited by this paper
• Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

  1989cited by this paper
• Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

  1989cited by this paper
• Intrahepatic chemotherapy for unresectable hepatocellular carcinoma

  1988cited by this paper
• Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

  1986cited by this paper
• Direct and indirect effects of interferon on in vivo murine tumor cell growth.

  1985cited by this paper
• A phase II trial of high‐dose intravenous interferon alpha‐2 in advanced colorectal cancer

  1984influential reference
• Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.

  1983influential reference
• Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes

  1983cited by this paper
• Chemotherapy of large bowel cancer.

  1982cited by this paper
• Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins.

  1978cited by this paper
• 5‐Fluorouracil in hepatocellular carcinoma. Report of twenty‐one cases

  1977cited by this paper
• A phase III study comparing the clinical utility of four regimens of 5‐Fluorouracil. A preliminary report

  1977cited by this paper
• Editorial: Large-bowel cancer-The current status of treatment.

  1976cited by this paper
• Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

  1972cited by this paper
• Treatment of carcinoma of the esophagus.

  1971cited by this paper
• Comparison of antimetabolites in the treatment of breast and colon cancer.

  1967cited by this paper

• Exploring the protective association between COVID-19 infection and laryngeal cancer: insights from a Mendelian randomization study

  2024cites this paper
• Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2

  2022cites this paper
• Multimodality Treatment in Pancreatic and Periampullary Cancer

  2015cites this paper
• Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue

  2015cites this paper
• Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.

  2014cites this paper
• A case of hepatocellular carcinoma with portal vein tumor thrombosis successfully treated by a combination of intra-arterial infusion 5-fluorouracil, cisplatin, and systemic interferon-α therapies.

  2012cites this paper
• Interferon (Alpha, Beta and Omega) Receptor 2 Is a Prognostic Biomarker for Lung Cancer

  2012cites this paper
• Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.

  2011cites this paper
• Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer

  2011cites this paper
• Type I interferons as radiosensitisers for pancreatic cancer.

  2011cites this paper
• Treatment of Advanced Hepatocellular Carcinoma: Intraarterial Infusion Chemotherapy Combined with Interferon

  2010cites this paper
• Pilot study of combination chemotherapy of S‐1, a novel oral DPD inhibitor, and interferon‐α for advanced hepatocellular carcinoma with extrahepatic metastasis

  2008cites this paper
• Inhibitory Function of Interferon on Hepatocarcinogenesis

  2008cites this paper
• Interferon‐α and 5‐fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules

  2007cites this paper
• Combined intra‐arterial 5‐fluorouracil and subcutaneous interferon‐alpha therapy for highly advanced hepatocellular carcinoma

  2007cites this paper
• Type I Interferons in the Treatment of Pancreatic Cancer: Mechanisms of Action and Role of Related Receptors

  2007cites this paper
• Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resection

  2007cites this paper
• COMBINED HEPATOCELLULAR CARCINOMA AND CHOLANGIOCARCINOMA WITH PORTAL VEIN THROMBOSIS-A CASE REPORT-

  2007cites this paper